Health technology and value assessment can be conducted using a variety of methods. Dr. Malone will provide an overview of those methods and an introduction on how to interpret the results from cost-effectiveness studies. This webinar will also discuss issues with defining value for health technologies, especially pharmaceuticals.
By participating in this Webinar, attendees will be able to understand the importance of E&C in Medical Affairs and the amount of topics that this can cover
In this webinar, we explore two scenarios that can open Medical Affairs up to censure. Scenario one explores participation of commercial team members in Medical Advisory Boards and scenario two looks at the implications of a commercial team member requesting a medical team member to participate in a thought leader meeting.
By participating in this eCademy Webinar, attendees will be better able to:
After attending this eCademy Webinar, participants will be better able to:
Real world data (RWD), when captured and analyzed, produces the Real-World Evidence (RWE) that underpins the economic case for innovative medicines. Furthermore, RWD can inform the understanding of disease, help identify new therapeutic intervention points, and improve the efficiency of research and development (R&D), especially clinical trials. Unlocking the potential of any promising tool like RWD is not free from challenge and its full potential has yet to be realized. This Webinar aims to provide practical insight into the challenges surrounding RWD and RWE generation with interactive conversation on how individual companies are approaching these challenges.
By participating in this Webinar and/or the subsequent workshop at the MAPS EMEA 2018 Annual Meeting, attendees will be better able to:
Transitioning into new roles can prove a real test for even the most senior of executives. Up to 40% of new leaders fail, leave or burn out within the first 18 months. Painful and costly for all involved!
This webinar looks at how to navigate the “rollercoaster” of starting a new role, accelerating your career transition and building confidence early on.
Learning Objectives:
We explore during this Webinar how you can successfully navigate your next career transition:
Join Dr Omar Dabbous, Vice President, Health Economics and Outcomes Research (HEOR) and Real World Evidence (RWE) at AveXis, and Russell Becker, MA, HEOR Consultant, demonstrate HEOR’s front-and-center role in forging the modern healthcare agenda.
As healthcare systems worldwide become increasingly budget-constrained and cost conscious, stakeholders are placing greater emphasis on health economics demonstration and product potential in real-world practice. Once viewed solely as a support function, HEOR now often takes center stage in the internal decision-making process. As life sciences companies bring HEOR professionals and brand strategists together to formulate streamlined value chains, the function now provides essential data for licensing and R&D, as well as pricing and market access strategies, helps dictate research, planning and sales strategies.
This MAPS eCademy Webinar will:
Investigator Initiated Research is defined as ‘unsolicited‘, independent research where the Investigator or the Institution (academic, private or governmental) serves as the ‘Sponsor’ and a pharmaceutical or medical device company provides support in the form of drug/device and/or funding. A well-designed investigator initiated study can gain insights related to disease state and/or the clinical or scientific profile of a companies products. This may ultimately lead to improved evidence-based medicine and outcomes for patients.
We will discuss the process of investigator initiated research program followed across industry. The process is initiated externally by submission of IIR application via company website followed by internal company review and decision making process. This results in the execution of IIR study contract between the company and the Institution after which the study is initiated by the Investigator.
Making the best possible choices about health care requires the best possible evidence upon which to base these important decisions. High quality evidence comes from many sources including real world data (RWD). The sources of RWD are numerous including electronic health records, claims and billing data, product and disease registries and patient-reported data.
Analysis of RWD leads to clinical evidence known as real world evidence (RWE) regarding the usage and risks and benefits of a therapy. Under the right conditions, RWD and the RWE that follows may be used to support regulatory decisions and contribute to the knowledge of a drug or therapy. RWE may help to support improved decision-making about health and health care.
After completing this Webinar, participants will be able to:
•List the sources of real world data (RWD),
•Understand how real world evidence (RWE) can help to support a regulatory decision,
•Recognize when in the product life cycle RWD/RWE may be useful,
•Utilize a patient-centric framework to develop a RWD/RWE generation plan.